Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 12
2006 54
2007 39
2008 29
2009 35
2010 6
2011 35
2012 85
2013 151
2014 191
2015 251
2016 324
2017 376
2018 256
2019 312
2020 214
2021 193
2022 227
2023 232
2024 342
2025 244
2026 119

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,735 results

Results by year

Filters applied: . Clear all
Page 1
Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes.
Bakaloudi DR, Talukder R, Enright T, Leary JB, Makrakis D, Diamantopoulos LN, Hobeika C, Thomas VM, Swami U, Zakopoulou R, Bamias A, Brown JR, Pinato DJ, Latchford C, Jindal T, Koshkin VS, Murgić J, Miletić M, Frobe A, Johnson J, Zakharia Y, Alva A, Nguyen CB, Hui G, Drakaki A, Rodriguez-Vida A, Rey-Cárdenas M, Castellano D, Buznego LA, Duran I, Barrera RM, Marmolejo D, McKay RR, Stewart TF, Barata P, Epstein IB, Bellmunt J, Yu EY, Raychaudhuri R, Nadal R, Vakar-Lopez F, Gupta S, Wright JL, Khaki AR, Grivas P. Bakaloudi DR, et al. Clin Genitourin Cancer. 2025 Aug;23(4):102356. doi: 10.1016/j.clgc.2025.102356. Epub 2025 Apr 14. Clin Genitourin Cancer. 2025. PMID: 40378559
Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study.
Matsubara N, Loriot Y, Burgess EF, Park SH, Huddart RA, Ku JH, Tran B, Huang J, Huang YH, Nishimura K, Shimizu N, Xing N, Xue W, Hemaya R, Zhuo J, Deprince K, Triantos S, Siefker-Radtke AO. Matsubara N, et al. Clin Genitourin Cancer. 2025 Aug;23(4):102376. doi: 10.1016/j.clgc.2025.102376. Epub 2025 May 14. Clin Genitourin Cancer. 2025. PMID: 40483179 Free article. Clinical Trial.
Clinical Outcomes and Safety Profile of Neoadjuvant PD-1 Inhibitors Combined With VEGFR-TKI Versus VEGFR-TKI in Nonmetastatic Renal Cell Carcinoma.
Ng C, Peng C, Wang S, Zheng L, Qu L, Dong P, Ji C, Xiao J, Chen M, Jia Z, Zhang T, Hu X, Jing T, Xiong W, Wu J, Ye X, Li F, Yang Q, Tang Q, Zhao J, Wei X, Wu J, Cai W, Zhu G, Yu Z, Yan Z, Li C, Huang Z, Wang Z, Chen Y, Zhang J, Xue W, Bao Y, Qin C, Guo G, Huang J. Ng C, et al. Clin Genitourin Cancer. 2025 Aug;23(4):102353. doi: 10.1016/j.clgc.2025.102353. Epub 2025 Apr 16. Clin Genitourin Cancer. 2025. PMID: 40348728
Targeting KIT With Antibody-Drug Conjugates in Chromophobe Renal Cell Carcinoma.
Alchoueiry M, Mansour H, Khabibullin D, Han T, Chaturantabut S, Bzeih W, Tang Y, Williams JF, Hirsch MS, Priolo C, Sellers WR, Henske EP. Alchoueiry M, et al. Clin Genitourin Cancer. 2025 Aug;23(4):102359. doi: 10.1016/j.clgc.2025.102359. Epub 2025 Apr 15. Clin Genitourin Cancer. 2025. PMID: 40408838
2,735 results